Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study-Reference-Cited by-同舟云学术

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

Published:2022-10-29 Issue:1 Volume:129 Page:118-129
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Gümüş Mahmut¹^ORCID,Chen Chieh‐I²,Ivanescu Cristina³,Kilickap Saadettin⁴,Bondarenko Igor⁵,Özgüroğlu Mustafa⁶,Gogishvili Miranda⁷,Turk Haci M.⁸,Cicin Irfan⁹,Harnett James²,Mastey Vera²,Naumann Ulrike¹⁰,Reaney Matthew¹⁰,Konidaris Gerasimos¹¹,Sasane Medha¹²,Brady Keri J. S.¹³,Li Siyu²,Gullo Giuseppe²,Rietschel Petra²,Sezer Ahmet¹⁴

Affiliation:

1. Istanbul Medeniyet University, Faculty of Medicine Istanbul Turkey

2. Regeneron Pharmaceuticals, Inc Tarrytown New York USA

3. IQVIA Amsterdam The Netherlands

4. Department of Medical Oncology Istinye University Faculty of Medicine Liv Hospital Ankara Turkey

5. Dnipropetrovsk State Medical Academy City Multifield Clinical Hospital Dnipropetrovsk Ukraine

6. Cerrahpaşa Medical Faculty Istanbul University‐Cerrahpaşa Istanbul Turkey

7. High Technology Medical Centre Tbilisi Georgia

8. Department of Medical Oncology Bezmialem Vakif University Medical Faculty Istanbul Turkey

9. Department of Medical Oncology Trakya University İskender/Edirne Merkez/Edirne Turkey

10. IQVIA Reading UK

11. Sanofi Reading UK